SCLC
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 16/10/2020)
Non-metastatic stage
Currently no trials
Metastatic stage
Metastatic stage
1st line
Currently no trials
2nd line
RESILIENT (Ipsen)
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy.
3th line
Currently no trials
2nd line
RESILIENT (Ipsen)
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy.
3th line
Currently no trials